P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
TL;DR: Daratumumab is a human monoclonal antibody that has potent anti- Multiple Myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis.
Journal ArticleDOI
Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis
Ewan Forrest,Natasha Storey,Rohit A. Sinha,Stephen R. Atkinson,Nikhil Vergis,Paul G. Richardson,Steven Masson,Stephen D. Ryder,Mark Thursz,Michael Allison,Andrew Fraser,Andrew Austin,Anne McCune,Ashwin Dhanda,Dev Katarey,Jonathan R Potts,Sumita Verma,Richard D. Parker,Peter C. Hayes +18 more
TL;DR: Treating severe alcoholic hepatitis involves the exposure of patients to corticosteroids for 7 days to assess "response" to assess “response”.
Journal ArticleDOI
Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival
J. Wattacheril,Jennifer R. Kramer,Paul G. Richardson,B. D. Havemann,Linda K. Green,A. Le,Hashem B. El-Serag +6 more
TL;DR: Lagtimes to diagnostic colonoscopy have been used as practice performance measures in clinical practice and have been shown to improve the quality of treatment and reduce the risks of adverse events.
Journal ArticleDOI
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
Iris Breitkreutz,Marc-Steffen Raab,Sonia Vallet,Teru Hideshima,Noopur Raje,Dharminder Chauhan,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +8 more
TL;DR: The results indicate that AZD6244 inhibits OCL differentiation, formation and bone resorption, thereby abrogating paracrine MM cell survival in the bone marrow microenvironment and providing a preclinical rationale for the evaluation of AZD 6244 as a potential new therapy for patients with MM.
Journal ArticleDOI
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
Torben Plesner,Hendrik-Tobias Arkenau,Peter Gimsing,Jakub Krejcik,Charlotte Lemech,Monique C. Minnema,Ulrik Lassen,Jacob P. Laubach,Antonio Palumbo,Steen Lisby,Linda Basse,Jianping Wang,A. Kate Sasser,Mary E. Guckert,Howard Yeh,Tahamtan Ahmadi,Henk M. Lokhorst,Paul G. Richardson +17 more
TL;DR: This study assessed the updated safety and efficacy of DARA in combination with LEN/DEX following more than 12 months of exposure in patients with relapsed or RR MM.